|1.||Geba, Gregory P: 3 articles (02/2006 - 05/2004)|
|2.||Polis, Adam B: 3 articles (02/2006 - 05/2004)|
|3.||Palmer, R H: 3 articles (12/2001 - 01/2000)|
|4.||Gonzalo-Garijo, M A: 2 articles (01/2011 - 01/2007)|
|5.||Weaver, Arthur L: 2 articles (02/2006 - 11/2004)|
|6.||Petruschke, Richard A: 2 articles (02/2006 - 05/2004)|
|7.||Najarian, Daryl K: 2 articles (02/2006 - 05/2004)|
|8.||Kivitz, Alan J: 2 articles (11/2004 - 05/2004)|
|9.||Matsumoto, Alan K: 2 articles (11/2004 - 05/2004)|
|10.||Li, Duan: 2 articles (01/2004 - 11/2003)|
04/01/2000 - "Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety."
06/21/1997 - "Study Group of Nabumetone for Osteoarthritis of the Knee]."
07/01/1994 - "Efficacy and tolerability of nabumetone in the treatment of osteoarthritis of the knee joint: an open trial."
01/01/1984 - "A double-blind, placebo-controlled, crossover trial was carried out to assess the efficacy and tolerance of nabumetone in patients with osteoarthrosis of the hip or knee. "
02/01/2000 - "Nabumetone is a phototoxic nonsteroidal antiinflammatory drug used for the treatment of osteoarthritis. "
04/01/2003 - "Once-a-day dosing with nabumetone has been shown to be effective in adults with rheumatoid arthritis. "
06/15/1990 - "[Evaluation of tolerability and efficacy of a nabumetone preparation in the treatment of patients with rheumatoid arthritis]."
10/30/1987 - "The safety and efficacy of nabumetone and placebo were compared in a three-week, multicenter, double-blind, randomized, parallel evaluation involving patients with class II or III definite or classical rheumatoid arthritis. "
06/15/1990 - "In an open uncontrolled trial 30 patients (4 males, 26 females) aged 43-70 years suffering from active rheumatoid arthritis (diagnosis based on American Rheumatoid Association criteria) were treated with nabumetone (one 1 g capsule daily per os). "
10/30/1987 - "Forty-six patients with definite or classical rheumatoid arthritis were entered into a three-week, double-blind, randomized, parallel study of nabumetone, 1,000 mg at bedtime, compared with placebo. "
01/01/1999 - "The nabumetone 1500-mg group showed significantly greater improvement than the placebo group in bodily pain and social functioning (P < 0.05), and in vitality and MCS score (P < 0.01). "
07/01/1997 - "Distribution of quality of sleep and inactivity stiffness scores also improved relative to placebo at week 2. At the last visit, nighttime pain scores were still significantly better for patients receiving Naprelan versus nabumetone and placebo. "
07/01/1997 - "The nabumetone-treated group showed significant improvement over the placebo-treated group in only one primary assessment: mean change from baseline in patient's global assessment of OA at week 2. At week 2, significant differences favoring Naprelan versus nabumetone and placebo were measured in overall distribution of scores for joint tenderness and nighttime pain. "
11/01/1992 - "At the end point, nabumetone treated patients exhibited significant improvement in pain, Ritchie articular index, and duration of morning stiffness when compared to baseline. "
12/01/2009 - "This study found no significant differences in pain relief or tolerability between treatment with SAMe or nabumetone over 8 weeks in Korean patients with knee OA."
|4.||Soft Tissue Injuries (Soft Tissue Injury)
04/01/1993 - "To review the pharmacology, pharmacokinetic disposition, dosage recommendations, adverse effects, drug interactions, and efficacy of nabumetone in patients with selected rheumatic disorders and soft-tissue injuries. "
10/30/1987 - "Nabumetone in the treatment of skin and soft tissue injury."
01/01/2004 - "The clinical efficacy of nabumetone has also been evaluated in patients with ankylosing spondylitis, soft tissue injuries and juvenile RA. "
10/30/1987 - "Nabumetone, a new nonsteroidal anti-inflammatory agent, has been evaluated for the treatment of skin and soft tissue injury, including sports injury, in clinical trials involving nearly 1,000 patients. "
04/01/1993 - "Nabumetone also has been studied in ankylosing spondylitis and soft-tissue injuries. "
04/01/2013 - "Nabumetone inhibited stress-induced ulcer index at 25-mg/kg dose but stimulated dose-dependently mucus secretion. "
12/01/2001 - "In contrast, nabumetone impaired ulcer healing only at very high doses."
11/01/1992 - "The ulcer incidence after therapy with nabumetone, however, is far below the reported range. "
11/01/1992 - "Nabumetone was determined to be a safe NSAID that causes a low incidence of ulcers."
11/01/1992 - "The cumulative incidence of nabumetone-induced perforations, ulcers, or bleeds varied from 0.02 to 0.95%. "
|3.||Aspirin (Acetylsalicylic Acid)
|4.||Diclofenac (SR 38)
|5.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
|5.||Photochemotherapy (Photodynamic Therapy)